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Key points
 The mechanism of therapeutic efficacy of flecainide for catecholaminergic polymorphic
ventricular tachycardia (CPVT) is unclear.
 Model predictions suggest that Na+ channel effects are insufficient to explain flecainide efficacy
in CPVT.
 This study represents a first step toward predicting therapeutic mechanisms of drug efficacy in
the setting of CPVT and then using these mechanisms to guide modelling and simulation to
predict alternative drug therapies.
Abstract Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited
arrhythmia syndrome characterized by fatal ventricular arrhythmias in structurally normal hearts
during β-adrenergic stimulation. Current treatment strategies include β-blockade, flecainide and
ICD implementation – none of which is fully effective and each comes with associated risk.
Recently, flecainide has gained considerable interest in CPVT treatment, but its mechanism of
action for therapeutic efficacy is unclear. In this study, we performed in silico mutagenesis to
construct a CPVT model and then used a computational modelling and simulation approach
to make predictions of drug mechanisms and efficacy in the setting of CPVT. Experiments were
carried out to validate model results. Our simulations revealed that Na+ channel effects are
insufficient to explain flecainide efficacy in CPVT. The pure Na+ channel blocker lidocaine and
the antianginal ranolazinewere additionally tested andalso found tobe ineffective.Whenwe tested
lower dose combination therapy with flecainide, β-blockade and CaMKII inhibition, our model
predicted superior therapeutic efficacy than with flecainide monotherapy. Simulations indicate a
polytherapeutic approach may mitigate side-effects and proarrhythmic potential plaguing CPVT
pharmacological management today. Importantly, our prediction of a novel polytherapy for
CPVTwas confirmed experimentally. Our simulations suggest that flecainide therapeutic efficacy
in CPVT is unlikely to derive from primary interactions with the Na+ channel, and benefit may
be gained from an alternative multi-drug regimen.
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Introduction
First-linepharmacotherapy for treating catecholaminergic
polymorphic ventricular tachycardia (CPVT) patients
utilizes β-blockade at maximally tolerated doses; however,
30% of patients continue to experience arrhythmic
episodes andoften requiremechanical implantable cardio-
verter defibrillator (ICD) implantation (Liu et al. 2008).
β-Blockade is associated with fatigue, diminished physical
activity level and reduced quality of life, while ICD
discharge is associated with significant pain and anxiety,
which can induce additional episodes of electrical storm
(Sears et al. 1999; Nakamura et al. 2007).
CPVT is an inherited arrhythmia syndrome arising
from mutations in the ryanodine receptor (RyR2) as
well as the calcium buffer and regulator of RyR2,
calsequestrin (CASQ2). As its name suggests, CPVT sets
up a pathological substrate for arrhythmogenesis under
the influence of a catecholamine surge, which leads to
bidirectional and polymorphic ventricular tachycardia.
Sudden cardiac arrest and death are not uncommon for
individuals harbouring CPVT mutations, and a lethal
episode may present as the first manifestation of disease
(Priori et al. 2002).
Flecainide, a class IC antiarrhythmic suppresses the
emergence of CPVT in both mice harbouring the
CASQ2(−/−)mutation and humans with either a CASQ2
or RYR2 (S412G)mutation (Watanabe et al. 2009; van der
Werf et al. 2011). However, the mechanism and efficacy of
flecainide remain disputed. For example, Katz et al. (2010)
found little efficacy for CASQ2 subtypes, while Liu et al.
suggested virtually no effect on Ca2+ handling properties,
rather proposing that flecainide is effective due to its Na+
channel blocking properties (Watanabe et al. 2011; Liu
et al. 2011a). Still other studies demonstrated flecainide
interaction and blockade of RyR2 (Hilliard et al. 2010;
Galimberti & Knollmann, 2011; Mehra et al. 2014).
Studies of other class I antiarrhythmics showed that only
those that modulated RyR2 activity demonstrated efficacy
in models of CPVT, including propafenone (Hwang et al.
2011). Moreover, the type of interaction with the RyR2
was found to be significant as well; tetracaine, an RyR2
closed state blocker, failed to regulate Ca2+ properties in a
CASQ2(−/−) model of CPVT (Galimberti & Knollmann,
2011). The late Na+ channel blocker ranolazine has also
been studied for treatment of CPVT; however, two studies
reveal conflicting results: Parikh et al. (2012)demonstrated
strong interaction between ranolazine and RyR2, whereas
Galimberti & Knollmann (2011) failed to demonstrate
such an interaction.
Discrepant experimental observations, likely to be
due to different experimental set-ups and models of
CPVT, make reconciling the aforementioned studies
difficult. Thus, the focus of the present study is to
use a computational modelling approach to understand
the dominant mechanism(s) underlying antiarrhythmic
drug success and failure. In particular, is the effect of
flecainide to normalize aberrant Na+ channel activation
sufficient to explain observed clinical efficacy? The
latter would be particularly important, given the wealth
of clinical (The Cardiac Arrhythmia Suppression Trial
(CAST) Investigators, 1989; Nakamura et al. 2007) and
experimental data (Moreno et al. 2011) that reveal
flecainide-induced proarrhythmia. Finally, can we use
the model as a therapeutic prediction tool to optimize
a multidrug regimen in CPVT?
Methods
Ethics approval
Animal use was approved by the Institutional Animal
Care andUse Committee, Baylor College ofMedicine, and
conformed to theGuide for the Care and Use of Laboratory
Animals (National Research Council, 2011).
Experimental methods
Eight animals (six R176Q/+ and two wild-type (WT))
were studied with ECG telemetry as previously described
(van Oort et al. 2010). Telemeters (Data Sciences Inter-
national, St Paul, MN, USA) were implanted in the
abdominal cavity with subcutaneous lead placement in
a lead II configuration. Following telemetry implantation,
mice were injected with subcutaneous 0.3 mg kg−1
buprenorphine. The isoflurane was discontinued and
mice were placed on a warming pad with blow-by
oxygen.Theywereobserved continuouslyuntil awakewith
normal breathing pattern and spontaneous movement.
The mice were observed continuously for the first 2 h
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then daily for 7 days. Buprenophine, 0.2–0.3 mg kg−1
subcutaneous injection, was provided every 6–12 h for
the first 24 h. Ambulatory telemetry recordings were
obtained after all animals had at least 7 days’ recovery
from surgery and a 24 h baseline recording. Repeat
baseline recordings were obtained 15 min prior to all
injections.Mice were injectedwith a single intraperitoneal
(i.p.) dose of adrenaline (120 mg kg−1, Sigma-Aldrich, St
Louise, MO, USA) and caffeine (120 mg kg−1, Avantor
Performance Materials, Center Valley, PA, USA) in sterile
saline followed by continuous 24 h telemetry recordings.
After a 7daywash-out period, allmiceunderwent repeated
injections with pretreatment. Baseline ECG telemetry was
recorded for 15 min. Separate i.p. injections were given
of flecainide (12 mg kg−1, Sigma-Aldrich), metoprolol
(10 mg kg−1, Sigma-Aldrich) and KN-93 (30 μmol kg−1,
Calbiochem). All drugs were mixed in sterile water. After
30 min, mice were injected with a single i.p. dose of
adrenaline (2 mg kg−1) and caffeine (120 mg kg−1).
Following injection of adrenaline and caffeine, the mice
were monitored by telemetry for a total of 8 h. Data
collection was performed using Dataquest A.R.T. version
4.31 (Data Sciences International, St Paul, MN, USA).
Off-line analysis was performed by ECG Auto analysis
version 3.1 (EMKA technologies, Falls Church, VA, USA).
Molecular dynamics and free energy simulations
Force-field parameters for flecainidewere developed using
the general automated atomic model parameterization
(GAAMP) server developed by Huang & Roux (2013).
Briefly, all geometry optimization, charge fitting and
torsional parameter fitting were done using B3LYP
functional at the 6–31G∗(2d,2p) level of theory. Umbrella
sampling simulations for partitioning of the neutral and
cationic forms of flecainide into model POPE bilayer
(128 lipids) were performed using a protocol described
previously by Li et al. (2008). Harmonic constraints of
5 kcal (mol A˚2)−1 were applied to the drug’s centre of
mass along the reaction coordinate spanning 62 A˚ from
−31 A˚ to 31 A˚ normal to the membrane plane. We
used five starting conformations for the drug and 124
windows spaced every 0.5 A˚ to describe drug partitioning
into the bilayer. A flat-bottomed cylindrical restraint
with R = 15 A˚ was used to confine drug in the xy
plane along the reaction coordinate. It allows for good
sampling in a lateral plane. Each potential of mean force
(PMF) window was equilibrated for 2.5 ns in the pre-
sence of restraining potential and then subjected to a 5 ns
production run. The resulting 1D PMF was reconstructed
with the weighted histogram analysis method (WHAM)
(Roux, 1995). The WHAM convergence tolerance was set
at 0.0001 kcal mol−1. We used symmetrized density to
compute resulting PMFs. The statistical uncertaintieswere
estimated by separating the data into seven blocks and
were found to be within ±1.5 kcal mol−1 for neutral and
charged forms of flecainide, respectively.
Computational ventricular myocyte models
Briefly, we developed mouse and rabbit in silico
models of catecholaminergic polymorphic ventricular
tachycardia (CPVT) by ‘knocking out’ the SR Ca2+
buffer calsequestrin (Kornyeyev et al. 2012) in the
Morotti–Grandi mouse cardiac cell model (Morotti
et al. 2014) and in the Soltis–Saucerman rabbit cardiac
cell model (Soltis & Saucerman, 2010), respectively.
Flecainide interactions with the ryanodine receptor were
modelled assuming open state associations (Hilliard
et al. 2010). We also incorporated the model of the
cardiac Na+ channel and IKr and their interaction with
flecainide as previously (Moreno et al. 2011, 2013). We
utilized the Morotti–Grandi computational model for
mouse (Morotti et al. 2014) and the Soltis–Saucerman
computational model for rabbit (Soltis & Saucerman,
2010), which included all the relevant components
required for a detailed analysis, including accurate
cellular electrophysiology, Ca2+ handling (Shannon et al.
2004) and the cAMP-dependent protein kinase (PKA)
(Saucerman et al. 2003) and Ca2+/calmodulin-dependent
protein kinase (CaMKII) (Soltis & Saucerman, 2010)
phosphorylation pathways. The computational model for
flecainide interactionwith the cardiacNa+ channel is from
(Moreno et al.2011),with adaptations designed to recreate
the CPVT phenotype and flecainide’s interaction with
the RyR2, informed and validated by experimental data
(Hilliard et al. 2010; Hwang et al. 2011).
Wild-type Na+ channel models and inclusion of drug
binding
The wild-type drug-free Na+ channel model was used
as previously described (Moreno et al. 2013). The Na+
drug-channel model parameters for the on- and off-rates
of flecainide, ranolazine and lidocaine are taken from
experiments where available. These include diffusion rates
that indicate drug on-rates ‘kon’ = [drug] × D (diffusion
rate) and affinities (Kd) to discrete conformations that
determine drug off-rates ‘koff’ = Kd × D (diffusion
rate). Rates were also constrained by experimental data
(described in detail below) and microscopic reversibility
as in Colquhoun et al. (2004). The transition rates are
given in Table 1.
Flecainide. The flecainide model was used as previously
described (Moreno et al. 2011), but now includes a
drug-bound bursting regime (drug binding to red states
as indicated in Scheme 1; Tope 8 states are ‘normal’
gating mode, while red states indicate burst mode). Rate
constants in the upper (normal mode) states are from
C© 2015 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 1. Markov model transition rates (ms−1) for Drug free WT Na+ channel
States of Markov model Rate constants
IC3 →IC2, C3→C2, BC3→BC2 α11 = 8.5539/(7.4392e-2∗exp(-V/17.0)+2.0373e-1∗exp(-V/150))
IC2→IF, C2→C1, BC2→BC1 α12 = 8.5539/(7.4392e-2∗exp(-V/15.0)+2.0373e-1∗exp(-V/150))
C1→O, BC1→BO α13 = 8.5539/(7.4392e-2∗exp(-V/12.0)+2.0373e-1∗exp(-V/150))
IC2→IC3, C2→C3, BC2→BC3 β11 = 7.5215e-2∗exp(-V/20.3)
IF→IC2, C1→C2, BC1→BC2 β12 = 2.7574∗exp(-(V-5)/20.3)
O→C1, BO→BC1 β13 = 4.7755e-1∗exp(-(V-10)/20.3)
IC3→C3, IC2→C2, IF→C1 α3 = 5.1458e-6∗exp(-V/8.2471)
C3→IC3, C2→IC2, C1→IF β3 = 6.1205∗exp(V/13.542)
O→IF α2 = 13.370∗exp(V/43.749)
IF→O β2 = (α13∗ α2∗ α3)/(β13∗ β3)
O→IS αx = 3.4229e-2∗α2
IS→O βx = 1.7898e-2∗α3
C3, C2, C1, O → BC3, BC2, BC1, BO μ1 = 2.0462e-7
BC3, BC2, BC1, BO → C3, C2, C1,O μ2 = 8.9731e-4
Scheme 1
IC3 IC2
C2C3 C1 O IS
IF
BC3 BC2 BC1 BO
Moreno et al. (2011). Bursting state affinity for the charged
form of flecainide was initially set at the value found by
assuming the affinity of tonic block of late INa was equal to
Kd at−100mV. The value forKd,0 was then calculated and
used as an initial value in the optimization. For example,
the affinity of tonic block (TB) INa,L for WT is 44 μM
(Nagatomo et al. 2000); if that value is assumed to equal
Kd,−100mV,Kd,0,bursting was initially set at 3.202μM(e.g. the
Kd,0,bursting that would giveKd,−100mV,bursting = 44μM). The
optimizedKd,0,bursting was 95.2165μM.Full parameters are
given in Table 2.
Ranolazine. The ranolazine–Na+ channel drug inter-
action model was as previously described (Moreno et al.
2013) and the transition rates are given in Table 3.
Lidocaine. The wild-type lidocaine model was as pre-
viously described (Moreno et al. 2011), but now
includes a drug-bound bursting (lower 4 states) regime.
Non-bursting rates were from (Moreno et al. 2011).
Bursting state affinity for the charged form of lidocaine
was initially set at the value found by assuming the affinity
of tonic block of late INa was equal to Kd at −100 mV.
Kd,0 was then calculated and used as an initial value in the
optimization. For example, the affinity of TB INa,L for WT
is12 μM (Fedida et al. 2006); if that value is assumed to
equalKd,−100mV,Kd,0,bursting was initially set at 0.80μM(e.g.
the Kd,0,bursting that would give Kd,−100mV,bursting = 12 μM).
The optimized Kd,0,bursting was 0.9810 μM. The transition
rates are given in Table 4.
RyR2–flecainide drug-channel interaction model
development
The Shannon–Bers Markov model formulation of the
RyR2 (Shannon et al. 2004) was modified to include a
drug bound state DO with transitions kon = D × [drug]
and koff = D × IC50,drug to and from the open state O,
which represent the drug diffusing to the receptor and
binding or dissociating from the channel, respectively, as
done previously (Moreno et al. 2011). The diffusion rate
of flecainide (Scheme 2) was estimated at 5500 M−1 ms−1
(Zhu et al. 2006).
Scheme 2
[Ca]jct
[Ca]jct
kiSR Ca kiSR Ca
koSR Ca
2
koSR Ca
2
kim
RI
R O DO
kim
kom
kon
koff
kom
Isoproterenol-stimulated Ca2+ waves in CASQ2
knockout (KO) CASQ2(−/−) mice were inhibited by
flecainide with an IC50 of 2.0 ± 0.2 μM (Hwang et al.
2011), while other experimental preparations measured
an IC50 range from 2 to 17 μM (Brunton et al. 2010;
Hilliard et al. 2010; Hwang et al. 2011; Mehra et al. 2014).
Drug binding was modelled as open-state block, using
experimental data for drug affinity to the open state to
determine off and on rates, respectively. We also predicted
cases for variable flecainide IC50 = 3, 4, and 5 μM shown
in Fig. 1. We examined the cases of 3, 4 and 5 μM of
IC50 acting on each of the targets under the influence
of 1 μM isoproterenol, over a range of clinically relevant
pacing frequencies, from0.5 to 3.0Hz (30–180beatmin−1;
Leenhardt et al. 1995), at 0.01 Hz increments.
We assumed rapid partitioning of flecainide into its
charged (98% at pH 7.4, pKa = 9.3) and neutral (2%)
C© 2015 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 2. Markov model transition rates (ms−1) for Flecainide
Parameter Name Value
kon = kclosed, on [D+]∗Diffusion
koff = kclosed, off kd, open ∗Diffusion; (kdopen = 11.2e-6∗exp(-0.7∗V∗F/R∗T))
kbursting, on = kclosed bursting, on [D+]∗Diffusion
kbursting, off = kclosed bursting, off kdBursting,Open ∗Diffusion; (kdBursting,Open = 95.2165e-6∗exp(-0.7∗V∗F/R∗T))
kneutral, on [D]∗Diffusion
kneutral, off 400e-6∗Diffusion
kneutral, inactivated, on kneutral, on/2
kneutral, inactivated, off 5.4e-6∗Diffusion
kneutral, closed, on kneutral, on/2
kneutral, closed, off 800e-6∗Diffusion
Diffusion 5500 M−1ms−1
States of Markov model Rate constants
D+IC3 →D+IC2, D+C3→D+C2, α11
DIC3 →DIC2, DC3→DC2
D+IC2→D+IF, D+C2→D+C1, α12
DIC2→DIF, DC2→DC1
D+IC2→D+IC3, D+C2→D+C3, β11
DIC2→DIC3, DC2→DC3
D+IF→D+IC2, D+C1→D+C2, β12
DIF→DIC2, DC1→DC2
D+O→D+IS αx1 = 5.7839e-5∗αx
D+IS→D+O βx1 = 1.6689e-8 ∗βx
DO→DIS αx2 = 2.6126e-1 ∗αx
D+C1→D+O α13c = 3.6324e-3∗α13
DC1→DO α13n = 2.6452e+0∗α13
D+O→D+C1 β13c = (β13∗kcon∗koff∗α13c)/(kon∗kcoff∗α13)
DO→DC1 β13n = (β13∗kc on∗α13n∗k off)/(kc off∗α13∗k on)
DIS→DO βx2 = (βx∗k on∗ αx2∗ki off)/(αx∗ki on∗k off)
D+O→D+IF α22 = 1.4847e+3 ∗α2
DO→DIF α 22 = 4.2385e+1 ∗α2
D+IF→D+O β22 = (α13c∗ α22∗ α33)/(β13c∗ β33)
DIF→DO β 22 = (α 33∗α13n∗α 22)/(β 33∗β13n)
D+C3→D+IC3, D+C2→D+IC2, D+C1→D+IF β33 = 1.7352e-6 ∗β3
DC3→DIC3, DC2→DIC2, DC1→DIF β 33 = 2.1181e+0∗β3
D+IC3→D+C3, D+IC2→D+C2, D+IF→D+C1 α33 = 6.7505e-5 ∗α3
DIC3→DC3, DIC2→DC2, DIF→DC1 α 33 = (ki off∗ α3∗kc on∗ β 33)/(ki on∗kc off∗ β3)
D+IF→D+IT α44 = 2.4135∗ α2
D+IT→D+IF β44 = 4.9001e-2 ∗α3
DIF→DIT α 44 = 1.0326e-3 ∗α2
DIT→DIF β 44 = 2.1378e-2 ∗α3
fractions (Liu et al. 2003), diffusion of the neutral
component across the membrane, and equilibration on
the cytosolic side, resulting in equimolar concentrations
of flecainide inside and outside of the cell, consistent
with experimental observations and the mechanism of
flecainide’s interaction with the Na+ channel (Liu et al.
2003). The kinetics of the state transitions for the channel
are adjusted for temperature by a Q10 factor of 1.5
(Sitsapesan et al. 1991). The presence of a 20% RyR sub-
conductance state in response to flecainide binding of the
channel (Hilliard et al. 2010) is modelled at the whole cell
level as a reduction to 20% maximal conductance of the
channel.
In single channel simulations mimicking the
experimental conditions tested, the IC50 of 16 μM was
used to validate the model. It is important, however, to
justify the use of the 2 μM IC50 value used in cellular and
tissue level simulations.The16μMIC50 value corresponds
to single channel conditions (Hilliard et al. 2010), which
does not account for the influence of coupling between
adjacent ryanodine receptors on the kinetics of the channel
(Marx et al. 2001). Similarly, the IC50 value of 16 μM
C© 2015 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Table 3. Markov model transition rates (ms−1) for Ranolazine
Parameter Name Value
kon = kclosed, on [D+]∗Diffusion
koff = kclosed, off kd, open ∗Diffusion; (kdopen = 100.5e-6∗exp(-0.7∗V∗F/R∗T))
kbursting, on = kclosed bursting, on [D+]∗Diffusion
kbursting, off = kclosed bursting, off kdBursting,Open ∗Diffusion; (kdBursting,Open = 1.5012e-6∗exp(-0.7∗V∗F/R∗T))
kneutral, on [D]∗Diffusion
kneutral, off 400e-6∗Diffusion
kneutral, inactivated, on kneutral, on
kneutral, inactivated, off 5.4e-6∗Diffusion
kneutral, closed, on kneutral, on
kneutral, closed, off 800e-6∗Diffusion
Diffusion 5500 M−1ms−1
States of Markov model Rate constants
D+IC3 →D+IC2, D+C3→D+C2, α11
DIC3 →DIC2, DC3→DC2
D+IC2→D+IF, D+C2→D+C1, α12
DIC2→DIF, DC2→DC1
D+IC2→D+IC3, D+C2→D+C3, β11
DIC2→DIC3, DC2→DC3
D+IF→D+IC2, D+C1→D+C2, β12
DIF→DIC2, DC1→DC2
D+O→D+IS αx1 = 4.4923e+3 ∗αx
D+IS→D+O βx1 = 2.7031e-1 ∗βx
DO→DIS αx2 = 1.4947e+1 ∗αx
D+C1→D+O α13c = 3.6811∗α13
DC1→DO α13n = 2.3570e+2∗α13
D+O→D+C1 β13c = (β13∗kcon∗koff∗α13c)/(kon∗kcoff∗α13)
DO→DC1 β13n = (β13∗kc on∗α13n∗k off)/(kc off∗α13∗k on)
DIS→DO βx2 = (βx∗k on∗ αx2∗ki off)/(αx∗ki on∗k off)
D+O→D+IF α22 = 6.8705e+4 ∗α2
DO→DIF α 22 = 2.1182e+2 ∗α2
D+IF→D+O β22 = (α13c∗ α22∗ α33)/(β13c∗ β33)
DIF→DO β 22 = (α 33∗α13n∗α 22)/(β 33∗β13n)
D+C3→D+IC3, D+C2→D+IC2, D+C1→D+IF β33 = 1.7561e-1 ∗β3
DC3→DIC3, DC2→DIC2, DC1→DIF β 33 = 1.2197e-3∗β3
D+IC3→D+C3, D+IC2→D+C2, D+IF→D+C1 α33 = 4.0832e-2 ∗α3
DIC3→DC3, DIC2→DC2, DIF→DC1 α 33 = (ki off∗ α3∗kc on∗ β 33)/(ki on∗kc off∗ β3)
for spark inhibition in permeabilized myocytes cannot
be used, due to the constant maintenance of [Ca2+] in
those experiments – the high concentration of Ca2+ used
to elicit consistent Ca2+ sparks in experiments is static
and is an unrealistic representation of paced myocytes
(Galimberti & Knollmann, 2011). The high external Ca2+
concentration used would cause a higher IC50 than that
seen using a lower Ca2+ concentration in the intact myo-
cyte used to generate Ca2+ waves during diastole, due to a
persistently overactive ryanodine receptor by constitutive
cytosolic activation.
Thus the measured IC50 for wave inhibition in the
isoproterenol-stimulated Ca2+ waves in CASQ2(−/−)
mice (IC50 = 2.0 ± 0.2 μM; Hwang et al. 2011), was used,
since it reflects realistic conditions for our model system.
Its weakness is that the IC50 does not separate out external
contributions to the IC50, such as lowered junctional
Ca2+ by INCX activity via lowered [Na+]. Experiments
in paced rat myocytes indicate that this contribution
may significantly influence flecainide’s ability to inhibit
spontaneous Ca2+ wave formation, and thus future work
will need to evaluate whether the contribution of INCX
regulation of Na+ is indeed significant in influencing
flecainide’s efficacy (Sikkel et al. 2013).
kCaSR = MaxSR − MaxSR − MinSR
1 +
(
EC50,SR
[Ca]SR
)H
SR
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Table 4. Markov model transition rates (ms−1) for Lidocaine
Parameter Name Value
kon = kclosed, on [D+]∗Diffusion
koff = kclosed, off kd, open ∗Diffusion; (kdopen = 318e-6∗exp(-0.7∗V∗F/R∗T))
kbursting, on = kclosed bursting, on [D+]∗Diffusion
kbursting, off = kclosed bursting, off kdBursting,Open ∗Diffusion; (kdBursting,Open = 0.981e-6∗exp(-0.7∗V∗F/R∗T))
kneutral, on [D]∗Diffusion
kneutral, off 400e-6∗Diffusion
kneutral, inactivated, on kneutral, on/2
kneutral, inactivated, off 3.4e-6∗Diffusion
kneutral, closed, on kneutral, on/2
kneutral, closed, off 900e-6∗Diffusion
Diffusion 500 M−1ms−1
States of Markov model Parameters
D+IC3 →D+IC2, D+C3→D+C2, α11
DIC3 →DIC2, DC3→DC2
D+IC2→D+IF, D+C2→D+C1, α12
DIC2→DIF, DC2→DC1
D+IC2→D+IC3, D+C2→D+C3, β11
DIC2→DIC3, DC2→DC3
D+IF→D+IC2, D+C1→D+C2, β12
DIF→DIC2, DC1→DC2
D+O→D+IS αx1 = 6.3992e-7∗αx
D+IS→D+O βx1 = 1.3511e+0 ∗βx
DO→DIS αx2 = 1.3110e-1 ∗αx
D+C1→D+O α13c = 5.6974e-3∗ α13
DC1→DO α13n = 8.4559e+1∗α13
D+O→D+C1 β13c = (β13∗kcon∗koff∗α13c)/(kon∗kcoff∗α13)
DO→DC1 β13n = (β13∗kc on∗α13n∗k off)/(kc off∗α13∗k on)
DIS→DO βx2 = (βx∗k on∗ αx2∗ki off)/(αx∗ki on∗k off)
D+O→D+IF α22 = 6.7067e-6 ∗α2
DO→DIF α 22 = 1.7084e-5 ∗α2
D+IF→D+O β22 = (α13c∗ α22∗ α33)/(β13c∗ β33)
DIF→DO β 22 = (α 33∗α13n∗α 22)/(β 33∗β13n)
D+C3→D+IC3, D+C2→D+IC2, D+C1→D+IF β33 = 1.9698e-5 ∗β3
DC3→DIC3, DC2→DIC2, DC1→DIF β 33 = 4.8477e+0∗β3
D+IC3→D+C3, D+IC2→D+C2, D+IF→D+C1 α33 = 3.2976e+0 ∗α3
DIC3→DC3, DIC2→DC2, DIF→DC1 α 33 = (ki off∗ α3∗kc on∗ β 33)/(ki on∗kc off∗ β3)
koSRCa = koCa
kCaSR
kiSRCa = kiCakCaSR
dR
dt
=(kimRI−kiSRCa[Ca]jctR)−(koSRCa [Ca]2jct R−komO)
dO
dt
=
(
koSRCa [Ca]
2
jct R−komO
)
− (kiSRCa[Ca]jctO − kimI)
−(konO − koffDO)
dI
dt
= (kiSRCa[Ca]jctO − kimI)− (komI − koSRCa [Ca]2jct RI)
dDO
dt
= konO − koffDO
RI =
(
komI − koSRCa[Ca]2jctRI
)
− (kimRI − kiSRCa[Ca]jctR)
J SRCaRel = ks (O + 0.2 × DO) ×
(
[Ca]SR − [Ca]jct
)
J SRLeak = K SRleak
(
[Ca]SR − [Ca]jct
)
The parameters are presented in Table 5.
Simulation of IKr blockade
To simulate the effects of flecainide or ranolazine on IKr
current, we decreased the peak conductance, GIKr
in a concentration dependent fashion using a
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Figure 1. Testing IC50 of flecainide in the cell model for INa, RyR2 and both targets in combination
Voltage dynamics is shown for each IC50 case, and the voltage and Ca2+ transient maxima are binned for each
pacing frequency between 0.5 and 3 Hz during the second half of a 2 min simulation time course. A, CASQ2(−/−)
myocytes with 3, 4 and 5 μM IC50 effects on both Na+ channels and RyRs. B, flecainide interaction with just Na+
channels. C, flecainide concentrations acting on only RyRs.
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Table 5. Parameters for SR Ca2+ release
Parameter Name Value / Units
kon [D+]∗Diffusion
koff 0.011
Diffusion 5500 M−1ms−1
ks 25 ms−1
koCa 10 mM−2ms−1
kom 0.06 ms−1
kiCa 0.5 mM−1ms−1
kim 0.005 ms−1
EC50-SR 0.45 mM
MaxSR 15
MinSR 1
HSR 2.5
KSRleak 5.348e-6 ms−1
concentration–response relationship with a Hill
coefficient of 1 (n = 1) as follows:
G IKr = G IKr,max ×
(
1
1 + ([Drug]/IC50)n
)
where GIKr,max is the nominal conductance value from
the given rabbit ventricular myocyte model (Soltis &
Saucerman, 2010) and IC50 is the concentration of drug
that produces a 50% inhibition of IKr current. The IC50
values for the drug to inhibit IKr current are for flecainide
1.5μM(Belardinelli et al. 2013) and for ranolazine 12μM
(Rajamani et al. 2008).
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Figure 2. Dose–response curves for metoprolol on β1-receptor
blockade and KN-62 on CaMKII inhibition
A, dose–response curves for the effect of metoprolol on
β-adrenergic activity were extracted from an experimental model
(Abrahamsson et al. 1990). B, dose–response data were obtained
from (Davies et al. 2000) and fitted to a percentage block of CaMKII
for given doses of KN-62.
Simulation of effect of metoprolol on β-adrenergic
activity and CaMKII blocking effects of KN-62
We modelled the β1 and CaMKII blocking effects of
metoprolol (IC50 = 105 nM) and KN-62 (IC50 = 468 nM)
as a competitive inhibitor of β-agonist and limiter of free
endogenous total CaMKII, respectively. Dose–response
curves (Fig. 2) for the effect ofmetoprolol onβ-adrenergic
activity were extracted from an Emax experimental
model (Abrahamsson et al. 1990), where the percentage
inhibitionofEmax represents the fractionof ISO inhibition.
In preliminary tests of the computational model involving
myocyte pacing, 50 nM ISO achieved 98% of the maximal
response to agonist; ISO inhibitionwas thereforemodelled
as a percentage of 50 nM applied ISO. Thus, in Fig. 2A,
percentageβ1-receptor blockade refers to thepercentageof
β1-receptors that are competitively blockedbymetoprolol.
KN-62 was modelled as an inhibitor of endogenously
available CaMKII (Tokumitsu et al. 1990). Dose–response
data were obtained from Davies et al. (2000) and fitted
to a percentage block of CaMKII for given doses of
KN-62; similarly, percentage CaMKII inhibition in Fig. 2B
refers to the percentage of endogenous CaMKII that
is inhibited by KN-62. Data are from Abrahamsson
et al. (1990) (metoprolol) and Tokumitsu et al. (1990)
(KN-62). We applied the Emax model from Abrahamsson
et al. (1990) to determine our dose–response relation
as follows:
% β − Blockade or % CaMKII inhibition = E max × C
IC50 + C
where Emax = 100%, and C is the metoprolol or KN-62
concentration.
CPVT CASQ2(−/−) model development
The CPVT phenotype was modelled via a computational
CASQ2(−/−) (Knollmann et al. 2006) by modifying the
Soltis–Saucerman model (Soltis & Saucerman, 2010). We
set the calsequestrin buffer concentration and the time
derivative of the calsequestrin buffer concentration to 0.
While this hasnodirect effect on regulatingRyR2 function,
it was expected to still demonstrate a functional effect on
RyR2 activity because of alterations to intracellular SR
Ca2+. Equations for the regulation of Na+/K+-ATPase
activity by PKA as mediated by phospholemman were
incorporated from the Yang–Saucerman model (Yang &
Saucerman, 2012). Our previously validated Na+ channel
(Moreno et al. 2011) and modified RyR2 channel were
inserted into the cellular model (Soltis & Saucerman,
2010).
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Stochastic single channel RyR2 simulations
Individual RyR2 channels were modelled stochastically
in Monte Carlo simulations using Gillespie’s algorithm
(Gillespie, 1977). Parameters were constrained by fixed
concentrations of flecainide (0 and 50 μM), luminal
Ca2+ (1 mM), and junctional Ca2+ (0.1 μM), mimicking
experimental conditions (Hwang et al. 2011). Stochastic
error diminishes over a large number of simulations,
approaching the expected mean open time (To), mean
closed time (Tc), and open probability (Po) as derived by
the methods of Colquhoun & Hawkes (1981).
Cellular and tissue simulations
Mouse ventricular myocyte model. The INa channel was
replaced in the Morotti–Grandi mouse cardiac cell model
(Morotti et al. 2014) with our published Markov model
(Moreno et al. 2013). We then adjusted three transition
rates for the mouse model to simulate the mouse INa
kinetics as follows: O→C1, β13 × 0.45; O→IF, α2 × 0.45;
O→IS, αx × 0.45. Virtual myocytes were paced using a
−9.5 pA pF−1 current stimulus for 5 ms in single cells for
150 s at 2Hz pacing frequency in the presence and absence
of drug and 0.5 μM isoproterenol (ISO).
Rabbit ventricular myocyte model. Virtual whole cells
and tissues (both WT and KO) were allowed to ‘rest’
without external stimuli for 10 min to establish initial
conditions. Cells were then virtually paced (using a
−80 pA pF−1 current stimulus for 0.5 ms in single cells
and −500 pA pF−1 stimulus for 2.0 ms in tissues) for
5 min at specific pacing frequencies in the absence of
drug or agonist. Cells were finally paced for an additional
2 min in the presence and absence of drug and 1 μM ISO.
Parameters including upstroke velocity, action potential
duration (APD) and thenumber of early anddelayed after-
depolarizations (EADs and DADs) were tracked over the
course of each simulation.
One-dimensional (1D) tissue was simulated as a fibre
of 165 cells (1.65 cm) (Glukhov et al. 2010) with
reflective boundary conditions. Transmural heterogeneity
was incorporated into the tissue by a linear decrease
to 25% maximal Ito conductance (Myles et al. 2010),
corresponding to a linear transition from epicardial to
endocardial tissue (Fedida & Giles, 1991) and an APD
gradient of 205–224 ms. The diffusion coefficient Dx
was set to 0.002 cm2 ms−1 to establish a conduction
velocity of 61–73 cm s−1 (epicardium–endocardium in
WT conditions) (Brugada et al. 1990).
Code for simulations and analysis was written in C++
and MATLAB 2014a (The Math Works, Inc., Natick, MA,
USA). Code was run on an Apple Mac Pro machine with
two 2.93 GHz 6-Core Intel Xeon processors, and an HP
ProLiant DL585 G7 server with a 2.3 GHz 48-core AMD
Opteron processor. Code was compiled with the Intel
ICC compiler 2013. Numerical results were visualized
using MATLAB R2014b. All source code used in this
paper is available online or can be obtained by emailing
ceclancy@ucdavis.edu.
Results
Wemodelled the interaction between flecainide and RyR2
by modifying the Shannon–Bers model of the cardiac
RyR2 channel (Shannon et al. 2004) (see Methods) that
reproduces gain and fractional SR Ca2+ release, and
includes regulation by both luminal and junctional Ca2+
fractions. Based on experimental data, drug binding was
modelled as voltage-independent open-state block that
results in a 20% subconductance state (Hilliard et al.
2010; Hwang et al. 2011; Mehra et al. 2014). A different
recent study suggested that flecainide does not block
the RyR (Bannister et al. 2015). These effects are also
included in the cellular level simulations as no RyR block
by flecainide.
This assumption resulted in predictions of drug effects
that were consistent with experiments in single channel
lipid bilayer studies (Hilliard et al. 2010). Stochastic
Monte Carlo simulations reveal intermittent closures that
interrupt channel openings, corresponding to flecainide
binding and unbinding the open-state (Fig. 3A) (Hwang
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Figure 3. Simulated interaction of flecainide with single
ryanodine receptors
A, experimental single RyR channels in bilayers (left) compared with
stochastic model simulations (right), in the absence (top) and
presence (bottom) of 50 μM flecainide. B, measured and simulated
dose dependence of flecainide on channel open probability (Po, left),
mean open time (middle, To), and mean closed time (Tc).
Experimental data points (circles) and simulated results from
1,000,000 stochastic openings and closures at concentrations as
indicated (lines). Experimental data are from Hilliard et al. (2010 and
Hwang et al. (2011).
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et al. 2011). Figure 3B shows model predictions (lines)
closely match experimental measurements (symbols) of
drug concentration-dependent effects on channel open
probability (left) and channel mean open time (middle)
(Hwang et al. 2011). Mean closed time displays no dose
dependence in this binding scheme, as in experimental
findings (Fig. 3B, right). We modelled flecainide inter-
actions with the Na+ and hERG K+ channel as described
previously (Moreno et al. 2011) (Moreno et al. 2013).
We generated a virtual calsequestrin knockout
mouse cardiac myocte (CASQ2(−/−)) by setting the
concentration of CASQ to zero in the Morotti–Grandi
model of the mouse ventricular myocyte, which includes
the β-adrenergic signalling and CaMKII pathways
(Morotti et al. 2014). We then predicted the effects of the
virtual CASQ2(−/−) on electrical and Ca2+ dynamics.
Figure 4A–D shows action potentials (APs) (top) and
Ca2+ transients (bottom) of cells paced at a frequency
of 2 Hz. As expected, the Ca2+ transient amplitude
increases upon application of 0.5 μM isoproterenol
(ISO) (Fig. 4B). In the absence of ISO, CASQ2(−/−)
myocytes demonstrate reduced but intact Ca2+ trans-
ients and APs compared with control (compare Fig. 4C
to Fig. 4A) consistent with experimental observations
in CSQN mutant and CSQN underexpression mouse
myocytes (Viatchenko-Karpinski et al. 2004; Terentyev
et al. 2008; Gyorke & Terentyev, 2008). Consistent
with multiple experimental observations, application of
0.5μM ISO induces spontaneous Ca2+ release events (red
arrows Fig. 4D, bottom), which drive afterdepolarizations
(Knollmann et al. 2006;Gyorke&Terentyev, 2008;Hilliard
et al. 2010; Liu et al. 2013). Following development of
the virtual mouse model of CPVT, which is validated by
many published experimental data, we generated a virtual
calsequestrin rabbit knockout (CASQ2(−/−)). This
approach allows for cross species testing, e.g. to predict
how larger animals (more ‘human-like’) would respond,
and to also look for model independence of our findings.
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Figure 4. An in silico calsequestrin (CASQ2(−/−)) knockout model recapitulates the CPVT phenotype
In each panel, simulated membrane voltage (top) and intracellular Ca2+ transients (bottom) are shown during
2 Hz pacing in the mouse virtual myocyte (A–D) and 1 Hz in the rabbit virtual myocyte (E–H). A, simulated control
mouse ventricular myocytes. B, control mouse cell with 0.5 μM simulated isoproterenol (ISO). C, simulated CASQ2
knockout mouse. D, 0.5 μM ISO applied to the simulated CASQ2 knockout mouse. E, simulated control rabbit
ventricular myocytes. F, control rabbit cell with 1 μM simulated isoproterenol (ISO). G, simulated CASQ2 knockout
rabbit. H, 1 μM ISO applied to the simulated CASQ2 knockout rabbit. Red arrows indicate spontaneous triggers.
Black arrow is the final stimulus.
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The rabbit model was constructed by setting the
concentration of CASQ to zero in the Soltis–Saucerman
model of the rabbit ventricular myocyte, which contains
the β-adrenergic signalling and CaMKII pathways.
Figure 4E–H shows simulated rabbit APs (top) and Ca2+
transients (bottom) of control cells paced at a frequency
of 1 Hz. As observed in the mouse model, the Ca2+ trans-
ient amplitude increases upon application of 1 μM ISO
(Fig. 4F). In the absence of ISO, CASQ2(−/−) myocytes
demonstrate morphologically similar Ca2+ transients and
APs to control (compare Fig. 4G to Fig. 4E). No differences
were found with other pacing frequencies. Consistent
with experimental observations (Kornyeyev et al. 2012),
application of 1 μM ISO induces spontaneous Ca2+
release events (red arrows Fig. 4H, bottom), which drive
depolarizations that trigger APs (red arrows in Fig. 4H,
top).
Recent publications have suggested that flecainide may
be insufficiently concentrated inside the cell to affect
the RyR directly (Liu et al. 2011a, 2012). Thus, we
employed a novel atomic scale modelling approach to
compute free energy profiles for flecainide transport in the
extracellular, membrane and intracellular compartments
(Fig. 5A).
With a pKa value of 9.8, 97% of flecainide will exist
in the protonated form at physiological pH. However,
recent studies suggest that the hydrophobic environment
of the lipid bilayers promotes stabilization of the neutral
form, allowing for flecainide entry upon deprotonation.
To assess feasibility of this mechanism, we determined
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Figure 5. Atomic scale prediction of flecainide
transport across the membrane
A, visualization of flecainide transport. B, the
difference between the potentials of mean force
(PMF (Z)) across the bilayer, and position-dependent
free energies for charged and neutral flecainide
(GA) at the membrane interface (site 1) and
hydrophobic core of the bilayer (site 2). Relative
fractions of neutral to charged drug (Fqo/Fq+) in the
aqueous solution (red), site 1 (blue) and site 2 (black)
are shown.
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the underlying thermodynamics governing flecainide
movement on the surface and in the hydrophobic core of
the membrane and the barriers associated with transport
of cationic or neutral forms.
Force (PMF) (or Potential mean force free energies
(GA)) for partitioning of charged and neutral
flecainide
Both forms of flecainide display preference for inter-
facial partitioning with stabilization of about 8 and 11
kBT for charged and neutral flecainide, respectively. The
simulations show that concentration of neutral flecainide
will increase substantially on the surface as compared to
the bulk phase and will be predominant in the hydro-
phobic core of the bilayer (site 2). There is a substantial
penalty for protonated drug to cross a hydrophobic core,
although it will act as a sink for a neutral flecainide with
a very small crossing barrier for the drug (2kBT not
shown).
The difference between the potentials of mean force
(PMF (Z)) across the bilayer, and position-dependent
free energies for charged and neutral flecainide (GA)
at the membrane interface (site 1) and hydrophobic
core of the bilayer (site 2) are shown in Fig. 5B. We
calculated the pKa shift due to drug deprotonation upon
partitioning into lipid bilayers from the difference between
the position-dependent free energies for charged and
neutral flecainide (GA).
G deprot = WFlec0 (z) − WFlec+ (z)
pK A = G deprot
2.3 kBT
pKa values are also indicated as relative fractions of
neutral to charged drug (Fqo/Fq+) in the aqueous solution
(red), site 1 (blue) and site 2 (black) in Fig. 5B. The pKa
shift is close to zero in the bulk (as expected) and then
sharply drops at site 1. This indicates that flecainide will
readily lose its proton in the membrane environment.
Is diffusion of neutral flecainide sufficient for effective
accumulation? We estimated diffusion coefficients from
local friction factors along the reaction coordinate in free
energy simulations (from fluctuations in the constraining
force) (Boggara & Krishnamoorti, 2010). The diffusion
coefficient for flecainide was calculated as 4.9 × 10−7
cm2 s−1 in the bilayer, about an order of magnitude
lower than bulk water similar to previously reported
values for various drugs (Boggara & Krishnamoorti,
2010). Flecainide is predicted to undergo extremely rapid
equilibration.
We next predicted the effects of flecainide on control
and CASQ2(−/−) rabbit ventricular myocyte models
for clinically relevant frequencies at a high therapeutic
dose of flecainide (2 μM). In order to map the action
potential (AP) dynamics–frequency relationship for the
CPVTCASQ2(−/−) with flecainide, themaximumvalues
of the voltage following the upstroke of the AP were
collected during the second half of a 2 min simulation and
binned vertically for each constant pacing frequency; for
clarity, only steady state behaviour is shown (t= 60–120 s).
In the control simulation there was a stimulus to AP ratio
of 1:1 (Fig. 6A). The time course of AP at 2 Hz (grey
line) is shown on the left (Fig. 6A, C, E, G and I). The
peak of the calcium transient was similarly monitored
(control – Fig. 6B), with the time course of the calcium
transient at 2 Hz (grey line) in the left of each of the right
panels (Fig. 6B, D, F, H and J).
In the absence of drug, CASQ2(−/−) myocytes
displayed triggered APs at frequencies greater than
0.95 Hz (notice the horizontal line in the plot at
frequencies slower than 0.95 Hz, corresponding to a
stimulus to AP ratio of 1:1), when challenged by 1 μM
ISO (Fig. 6C). Pathological electrical activity was pre-
ceded by spontaneous Ca2+ release events from the
RyR2 (Fig. 6D), which, when resulting in a sufficient
release of Ca2+, can integrate in time to induce electro-
genic forward-mode sodium–calcium exchange current
(3 inward Na+/1 outward Ca2+) and depolarize the cell,
ultimately activating INa.
Application of a high therapeutic dose flecainide
(2 μM), acting on the rabbit RyR2, IKr and INa rectified
the electrical activity at all frequencies tested (Fig. 6E).
The electrical stability coincided with suppression of
diastolic Ca2+ release, but was also accompanied by a
markedly reduced Ca2+ transient (Fig. 6F). The thera-
peutic range of plasma concentrations for flecainide is
0.5–2.0 μM (Brunton et al. 2010). We examined the cases
of 0.5, 1.0 and 1.5 μM flecainide acting on each of the
targets under the influence of 1 μM isoproterenol, over
a range of clinically relevant pacing frequencies, from
0.5 to 3.0 Hz (30–180 beats min−1; Leenhardt et al.
1995), at 0.01 Hz increments (Fig. 7). Low dose flecainide
(0.5 μM) failed to suppress Ca2+ alternans, a marker of
proarrhythmia (Chudin et al. 1999), which emerged at
frequencies greater than 1.6 Hz and suggests incomplete
efficacy in the lower range of therapeutic dosing (Fig. 7A).
We next simulated drug action on the Na+ current or
RyR alone to determine the contributions of each target to
drug efficacy. The rabbit model predicted that neither the
high dose of flecainide (2 μM in Fig. 6G and H), nor any
lower concentrations, when tested on Na+ current alone,
eliminated pathological activity at all pacing frequencies
(Fig. 7B). As expected from flecainide’s use-dependent
blocking behaviour of INa, higher concentrations and
fasterpacing frequencies eliminated somearrhythmogenic
behaviour, but DADs and triggered action potentials
persisted. Derangement of Ca2+ activity also persisted,
and was largely unaffected by drug effects on the Na+
current (Fig. 6H).
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Selective application of flecainide on RyR2 yielded
results comparable to the case flecainide acting on both
targets (compare Fig. 6I and J (selective RyR2) with Fig. 6E
andF (both targets)).Mid- andhigh-doseflecainide acting
on the RyR2 alone resolved pathological behaviour at
the cellular level, though Ca2+ alternans and DADs still
emerged at lower doses (Fig. 7C).
We next modelled the physiological effects of acute
application of isoproterenol on heart rate, mimicking
acute sympathetic stimulation. In Fig. 8, rabbit cells were
paced to steady-state (for 500 s) at 1 Hz and then sub-
jected to isoproterenol and an increase in pacing frequency
(cycle length = 600 ms). Compared with control virtual
cells that responded uneventfully to sympathetic challenge
(Fig. 8A), the virtual CASQ2(−/−) CPVT mutation
generated multiple spontaneous APs, observed in the
histogram of peak voltages in time (left side of left panels)
and in the time course of themembrane potential (right of
left panels during the time indicated by the boxed region
in the left panels). As observed for steady-state pacing,
simulated 2 μM flecainide application on both the Na+
current andRyR (Fig. 8C) normalized aberrant behaviour,
while flecainide effects on the Na+ channel alone were
insufficient (Fig. 8D). A dose of 2 μM flecainide acting
on the RyR alone normalized the membrane potential
and prevented spontaneous Ca2+ release (Fig. 8E). We
also tested different pacing cycle lengths from 300 ms to
500 ms, and found similar results (data not shown).
We next predicted the effects of flecainide in a rabbit
one-dimensional (1D) transmural heterogeneous tissue.
Stimulation was applied to the endocardial site of the
CASQ2(−/−) rabbit tissue at 2 Hz (120 beats min−1)
with 1 μM ISO, in the presence or absence of flecainide.
Spontaneous Ca2+ releases from the RyR2 often resulted
in sufficient calcium loading to drive inward INCX, causing
DADs that were occasionally sufficient in amplitude to
activate Na+ channels for a triggered AP (red arrows –
Fig. 9A).
Flecainide at 2 μM acting on both the Na+ channels
and the RyRs suppressed propagated arrhythmogenic
activity by regulating underlying SRCa2+ release (Fig. 9B).
Also consistent, 2 μM flecainide acting on INa alone
did not prevent spontaneous Ca2+ release and DADs
(Fig. 9C). However, 2 μM flecainide acting on the
50
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Figure 6. Model prediction of flecainide mechanism
The time course of action potentials is in left columns
and calcium transients (CaTs) in right columns at 2 Hz.
Voltage and Ca2+ transient dynamics over a range of
physiological frequencies is shown to the right of each
simulated time course at 2 Hz: the voltage maxima are
binned for each pacing frequency between 0.5 and 3 Hz
during the second half of a 2 min simulation time
course. A and B, control APs, CaTs. C and D,
CASQ2(−/−) APs, CaTs. E and F, CASQ2(−/−) myocyte
APs and CaTs with high clinical dose (2 μM) flecainide
effects on both Na+ channels and RyRs. G and H, high
dose flecainide acting only on Na+ channels. I and J,
high dose flecainide (2 μM) on only RyRs.
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RyR2 alone was sufficient for therapeutic suppression
of DADs and triggered APs (Fig. 9D). Notably, 2 μM
flecainide acting on INa (e.g. Fig. 9B and C) slowed tissue
conduction velocity from 66 to 44 cm s−1 as compared
with 2 μM flecainide acting on RyR2 alone, consistent
with well-documented detrimental conduction velocity
in coupled tissue (Starmer et al. 1991;Moreno et al. 2011).
We further probed concentration dependence of our
RyR2-specific effects of flecainide, and found strong dose
dependence. Subthreshold DADs arising from spatially
discordant Ca2+ alternans emerged in the presence of
0.5 μM and 0.65 μM flecainide acting on RyR2 (Fig. 10),
alone and in combination with INa block (not shown).
Figure 10B and D show the time course of the Ca2+
mediated alternans development for 0.5μMand 0.65μM
flecainide, respectively, acting on RyR2 alone.
Given the therapeutic potential of flecainide to
normalize Ca2+ anomalies in the CPVT-linked
CASQ2(−/−), we set out to predict whether other
Na+ channel blockers might suppress emergent-triggered
activity in rabbit ventricular myocyte models. We
simulated thepureNa+ channel blocker lidocaine (20μM)
and the lateNa+ current/hERGchannel blocker ranolazine
(5 μM) (Moreno et al. 2013). Lidocaine and ranolazine
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Figure 8. Simulation of the physiological effects of isoproterenol on heart rate
Five hundred beats were paced in control cells at Basic Cycle Length (BCL) 1000 ms (1 Hz) without ISO; cycle
length was abruptly decreased to 600 ms with concomitant application of ISO (1 μM). Peak voltages in time are
shown in the left columns, and a representative time course (expanded rectangle of left panels) of the membrane
potential action potentials is in the 2nd column. Corresponding peak Ca2+ transients are in column 3, with a
representative time course shown in the far right columns. The grey arrow in each panel denotes onset of pacing
acceleration and application of ISO.
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have both failed to demonstrate efficacy in the suppression
of Ca2+ wave formation (Galimberti &Knollmann, 2011).
For both lidocaine and ranolazine devoid of RyR2 inter-
action, our results mimicked selective INa inhibition by
flecainide. Lidocaine (Fig. 11A) and ranolazine (Fig. 11B)
did not prevent spontaneous depolarizations at all
frequencies. Protocol is as in Fig. 6.
Low dose flecainide is predicted to be insufficient for
normalizing the CASQ2(−/−) CPVT mutation-induced
proarrhythmia in simulated cells and tissues. The
extensionof these results is that highdosesmaybe required
for clinical therapy, which may paradoxically promote
arrhythmia. β-Blockade is associated with suboptimal
management and pronounced side effects. Thus, we set
out to utilize modelling and simulation to guide a novel
form of virtual pharmacopoeia in an attempt to identify
alternative CPVT therapy.We considered combinations of
on-market or preclinical drugs that would cumulatively
regulate the RyR2 at lower concentrations, and mini-
mize risk associated with off-target interactions of each
drug.
CASQ2 (-/-) (1 μM ISO) 
2 μM Flecainide on
I
Na and RyR 
2 μM Flecainide on I
Na 
2 μM Flecainide on
RyR 
endo
epi
500 ms
endo
epi
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#165
500 ms
#1
cell
#165
A B
C D
Figure 9. Space–time representations of one-dimensional
simulations of flecainide effects on CPVT at BCL 500ms
For each set of panels, voltage time course is on the top, calcium
transient is on the bottom. A, simulated one-dimensional coupled
tissue harbouring the CASQ2(−/−) CPVT mutation in the absence of
drug. B, effect of flecainide (2 μM) on INa and RyR. C, flecainide
(2 μM) effects on INa alone. D, simulated effects of 2 μM flecainide
on the RyR alone. Red arrows indicate spontaneous DADs, triggered
action potentials and Ca2+ transients.
Weused the computationalmodel to test the hypothesis
that a multidrug combination of flecainide, β-blockade,
and CaMKII inhibition would demonstrate efficacy in
CPVT. Although little is known about CaMKII inhibition
in humans, the signalling molecule regulates many targets
and is highly distributed in the brain; thus it is expected
that high doses of CaMKII inhibition should be avoided
(Ledoux et al. 1999; Kaurstad et al. 2012). However, both
β-blockers and CaMKII inhibitors are classes of drugs that
functionally modulate RyR2 activity (Fig. 12A), and are
suggested to provide efficacy in the management of CPVT
(Pott et al. 2011; Liu et al. 2011b; Di Pasquale et al. 2013).
We modelled the β1-blocking effects of metoprolol
(IC50 = 105 nM) as a competitive inhibitor of β-agonist,
and CaMKII inhibition by KN-62 (IC50 = 468 nM) as
a limiter of free endogenous total CaMKII (see Fig. 2;
individual drug efficacy of β-blockade and CaMKII).
We tested in a full factorial combination: the range
of relevant concentration combinations in single cells
at 2 Hz 0–1 μM flecainide (0.1 μM increments),
0–420 nM metoprolol (corresponding to 0–80% block of
β-receptors, at 8% increments), and 0–468 nM KN-62
(corresponding to 0–50% CaMKII inhibition at 5%
increments). Among the combinations tested, a combined
dose of 0.5 μMflecainide, 70 nMmetoprolol and 312 nM
KN-62 resulted in controlled Ca2+ and voltage activity
over the duration of single cell pacing at 2 Hz (Fig. 12B).
Parameter space maps were generated for the three-drug
combination indicating ranges of dose to prevent DAD
formation and spontaneous Ca2+ release events. Among
the 1331 combinations tested, the surfaces shown in
Fig. 12C represent the efficacy of these combinations on
voltage (top row) and spontaneous Ca2+ releases (bottom
row). When the surface is dark blue, no DADs occurred
(voltage), while the dark blue surface in the bottom
panels of Fig. 12C indicates that no spontaneous Ca2+
release events occurred. Even for some drug combinations
that remediated DADs, spontaneous Ca2+ releases still
occurred (indicated by larger blue area in the DAD row
than the spontaneous Ca2+ release row). The effect of
flecainide alone is contained within these graphs where
the concentration of the other drugs is zero. The red stars
in Fig. 12C, right, show one predicted optimal therapeutic
combination, a combined dose of 0.5 μM flecainide,
70 nMmetoprolol and 312 nMKN-62, resulted in just one
effective combination that remediated Ca2+ and voltage
activity (indicated by a star). This is within a parameter
space of local minima, indicating eradication of single cell
proarrhythmia eventmarkers (e.g.DADsand spontaneous
Ca2+ release (SCaR) events).
Finally, we simulated our drug combination of 0.5 μM
flecainide, 70 nM metoprolol and 312 nM KN-62 in
CASQ2(−/−) in 1D tissue, and compared the results
with a simulated tissue pretreated with 0.5 μM flecainide
(Fig. 12D). Compared with flecainide alone, combination
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therapy was superior by (i) requiring a lower dose of
flecainide (and thus maintaining conduction velocity
41 cm s−1 for flecainide vs. 59 cm s−1 for combination
therapy); (ii) fully suppressing all DADs and triggered
APs; (iii) reducing APD90; (iv) normalizing [Ca]i; and (v)
preventing the occurrence of spatially discordant Ca2+
alternans (see Table 6).
We next tested if the rabbit model prediction for
flecainide, β-blockade and CaMKII polytherapy would
hold true in the computational mouse model, as a
test of the model independence of our findings. Just
as we observed for the rabbit model predictions, high
dose (2 μM) flecainide effects on both INa and the
RyR normalized the CASQ2(−/−) CPVT phenotype as
shown in Fig. 13A. Application of flecainide in the
mouse model did not affect the amplitude of the Ca2+
transients, consistent with experimental observations in
the mouse genetic models (Hilliard et al. 2010). Also
consistent, the effects of high dose (2 μM) flecainide
on INa alone was predicted to be insufficient for
normalizing the CASQ2(−/−) CPVT mutation-induced
afterdepolarizations and spontaneous Ca2+ release events
as shown in Fig. 13B. However, 2 μM flecainide acting on
the RyR2 alone was sufficient for therapeutic suppression
of DADs (Fig. 13C). Low dose 0.5μMflecainide acting on
INa and the RyR2 did not ablate spontaneous Ca2+ release
events as shown in Fig. 13D. We also tested if one of the
predicted polytherapy combinations that was found to be
effective in the rabbit model simulations was also effective
in themouse. The result, shown in Fig. 13E, shows that the
drug combination of 0.5μMflecainide, 70 nMmetoprolol
and 312 nM KN-62 in the mouse CASQ2(−/−)
virtual myocyte completely normalized the cellular
phenotype.
We next set out to experimentally test if the model
prediction for flecainide, β-blockade and CaMKII poly-
therapy would be effective in the R176Q/+ CPVT
experimental mouse model, an alternate CPVT genotype.
The results are shown in Fig. 14. A knock-in R176Q/+
CPVT mouse model was used (six R176Q/+, two WT).
Figure 10. Simulated effects of low clinical
dose flecainide effect on RyR only in CPVT
one-dimensional tissue
Ca2+ alternans developed slowly over time,
originating from the epicardial end (red arrows)
and continued to the endocardium (blue
arrows). A, simulated effects of low clinically
relevant dose of 0.5 μM flecainide acting on
the RyR alone on action potentials (top) and
Ca2+ transients (bottom). B, spatially
discordant Ca2+ alternans emerge over time.
Red arrows correspond to epicardial (Epi) Ca2+
alternans, while blue arrows correspond to
endocardial (Endo) Ca2+ alternans. Cell no.
160 (Epi) is shown from the time 53 s (bottom),
and Cell no. 1 (Endo) is shown from the time
63 s (top). C, a modest increase in flecainide
(0.65 μM) decreased the transient amplitude
difference between beats and prolonged the
onset of alternans. D, extended time course of
Ca2+ alternans development for 0.65 μM
flecainide on the RyR alone. Cell no. 160 (Epi) is
shown from the time 70 s (bottom), and Cell
no. 1 (Endo) is shown from the time 80 s (top).
In panels B and D, arrows mark the first
instance of alternans, which persist for the
duration of the simulation.
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R176/+micedevelopbidirectional ventricular tachycardia
(VT)with catecholamine provocation. At baseline, neither
the WT nor the R176Q/+ mice demonstrated ventricular
arrhythmias and average heart rate was 462 beats min−1
(R176Q/+) and 574 beats min−1 (WT) (Table 7). After
injection of adrenaline (2 mg kg−1 i.p.) and caffeine
(120 mg kg−1 i.p.), six of six R176Q/+ mice developed
bidirectional VT as shown in Fig. 14A and C. Ventricular
tachycardia initiated within 30 s to 6 min and lasted
between 1 and 51 min in length (average 21 min) with
an average ventricular rate of 807 beats min−1. Both
WT and R176Q/+ mice demonstrated T-wave alternans
lasting several hours after injection of adrenaline and
caffeine. After a 7 day wash-out, the mice were injected
with adrenaline and caffeine (2 mg kg−1 and 120 mg kg−1
i.p., respectively); however, 30 min prior, all mice were
given pre-treatment with i.p. injections of flecainide
(12 mg kg−1, Sigma-Aldrich), metoprolol (10 mg kg−1,
Sigma-Aldrich) and KN-93 (30 μmol kg−1, Calbiochem).
All mice demonstrated statistically significant PR, QRS
and QTc prolongation 30 min after administration of
flecainide, metoprolol and KN-93 (Table 8). Some mice
exhibited ST segment changes (data not shown). Heart
rates were lower after drug administration but not
significantly (Table 8). Adrenaline and caffeine following
pre-treatment with flecainide, metoprolol and KN-93
failed to induce ventricular tachycardia in all R176Q/+
mice. Mice demonstrated T-wave alternans (one WT and
five R176Q/+) and single premature ventricular contra-
ctions (four R176Q/+); however, higher-grade ectopy and
the typical bidirectional VT were not seen as shown in
Fig. 14B and C.
Discussion
The optimal pharmacological management of CPVT
remains a clinical challenge. The current mainstay of
pharmacotherapy often involves maximally tolerated
β-blockade despite high (30–50%) failure rates (Priori
et al. 2002; Liu et al. 2008). In conjunction with
pharmacotherapy, mechanical ICD implantation (Miyake
et al. 2013) and left cardiac sympathetic denervation
(Wilde et al. 2008) have been used clinically, but carry
inherent morbidity and fail to target the mechanistic
underpinnings of the CPVT arrhythmia triggers.
While alternative class I antiarrhythmics have been
suggested (Galimberti & Knollmann, 2011; Hwang et al.
2011), only flecainide has shownmoderate clinical success.
Its well-studied mechanism of action is inhibition of
the inward sodium current (INa), but data suggest that
flecainide interacts with IKr and RyR2 (Hilliard et al.
2010; Galimberti & Knollmann, 2011). Flecainide has
demonstrated lethal proarrhythmic effects in other patient
populations (Echt et al. 1991), and previous clinical
failures were largely the result of an incomplete under-
standing of the emergent proarrhythmic risk.
Recent studies have suggested that because flecainide
is 97–99% ionized at physiological pH, it is insufficiently
concentrated inside the cell to act on the RyR (Liu et al.
2011a, 2012), though the study cited as evidence showed
the opposite result (Liu et al. 2003). The authors made
permanently charged flecainide, which when applied
intracellularly (via a pipette) led to the same effect as
when the same concentration of unadulterated flecainide
was applied externally (in the bath). Permanently charged
Figure 11. Simulated high clinically relevant doses of lidocaine and ranolazine in CPVT myocytes
Single cell time course is shown at 2 Hz (left) and voltage and calcium transient maxima over a range of frequencies
(0.5–3 Hz, right). A and B, high clinically relevant dose (20 μM) of the pure Na+ channel blocker lidocaine on
voltage and Ca2+ transient, respectively. C and D, clinically relevant dose (5 μM) of the antianginal and late Na+
current blocker ranolazine on voltage and Ca2+ transient, respectively.
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Figure 12. Predicted low-dose polytherapy for CPVT
A, schematic diagram showing the primary targets of flecainide, metoprolol, and KN-62. B, prediction of low-dose
combined therapy on action potentials (top) and calcium transients (bottom) at 2 Hz C, 3 drug combination
parameter space simulated in single cells tracking the number of DADs (top) and spontaneous Ca2+ releases
(bottom). Red stars denote the location of the case in B of 0.5 μM flecainide, 70 nM metoprolol and 312 nM
KN-62. D, simulated tissue effects of low dose flecainide. E, predicted tissue effects of combined simulated therapy.
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Table 6. CASQ2(−/−) with ISO 1 μM at 2 Hz (rabbit)
Drug concentration CV (cm s−1) APD90 (ms) [Ca]i (μM)
Drug free 60 Triggered APs 0.6
Flecainide 2 μM 41 192.5 0.285
Flecainide 0.5 μM + 70 nM Metoprolol + 312 nM KN-62 59 177.8 0.55
flecainide had no effect when applied externally, showing
that the drug action cannot be via an extracellular path.
Here, we utilized a physics-based molecular dynamics
approach to simulate the partitioning of flecainide by
computing free energy profiles for flecainide trans-
port in the extracellular, membrane and intracellular
compartments (Fig. 5). The simulations suggest that
flecainide accumulates on the membrane surface in
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Figure 13. Simulated drug effects in mouse
ventricular myocytes
In each panel simulated membrane voltage (left) and
intracellular Ca2+ transients (right) are shown during
2 Hz pacing. A, CASQ2(−/−) myocyte APs and CaTs
with high clinical dose (2 μM) flecainide effects on
both Na+ channels and RyRs. B, high dose flecainide
acting only on Na+ channels. C, high dose flecainide
(2 μM) on only RyRs. D, low dose flecainide 0.5 μM
on both Na+ channels and RyRs. E, simulated test of
predicted polytherapy in mouse ventricular myocytes.
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cationic and neutral forms after which deprotonation
occurs at the surface binding site and promotesmembrane
crossing down the concentration gradient. The drug then
reacquires a proton once it is in the intracellular milieu.
This process is extremely rapid, occurring with a diffusion
coefficient of 10−7 cm s−1, only an order of magnitude
lower than in the bulk water.
Our predictions support the existing experimental data
suggesting the following cell entry model for flecainide
transport: (i) drug accumulates on the membrane surface
in cationic and neutral forms; (ii) deprotonation occurs at
the surface binding site (site 1) and promotes membrane
crossing down the concentration gradient; and (c) drug
acquires a proton once it is in the intracellular milieu.
As demonstrated in Fig. 4, virtual mouse and rabbit
CASQ2(−/−) cells with β-agonist display increased Ca2+
transients and spontaneous Ca2+ release events, which
are sufficient to drive triggered cellular electrical activity,
and reproduce clinical behaviour of the CVPT phenotype
(Liu et al. 2011a). The absence of calsequestrin as a
buffer speeds up the dynamics of SR refilling, providing
more interaction time for SR Ca2+ to activate the RyR2,
and results in functionally upregulated RyR2 activity.
The resulting spontaneous Ca2+ release events and
depolarizations of the membrane persist after cessation of
pacing, owing to cyclic refilling of the SR, spontaneous
release of Ca2+ into the cytoplasm via the RyR2,
activation of INa by inward INCX, influx of Ca2+ via
activation of ICaL and reuptake of Ca2+ into the SR via
SERCA. It is important to note that diastolic intervals
in the rabbit are longer than in the mouse, and the
model predicted that they could allow sufficient time
to promote spontaneous diastolic release and triggered
activity.Ourmodelpredicted thathighdoseflecainidepre-
vents aberrant spontaneous Ca2+ releases with resultant
resolution of triggered AP activity in single virtual myo-
cytes of mouse and rabbit and in rabbit transmural 1D
virtual cardiac tissue (see Figs 6, 8 and 9), consistent
with experimental data (Hilliard et al. 2010; Galimberti
& Knollmann, 2011).
There is considerable disagreement in the literature as
to whether the antiarrhythmic effects seen with flecainide
are predominately the result of Na+ channel blockade,
RyR2 blockade, or both. Studies byWatanabe et al. (2009)
and others (Hilliard et al. 2010; Galimberti & Knollmann,
2011; van der Werf et al. 2011) have documented a sub-
stantial interaction between flecainide and RyR2. They
proposed that flecainide acts as a RyR2 open state
blocker, with resultant increase in Ca2+ spark rate, a
decrease in Ca2+ spark mass and disruption of Ca2+ wave
propagation.
Other studies have failed to document any effects
of flecainide on RyR or Ca2+ handling, and suggested
flecainide’s efficacy is almost entirely due to its Na+
channel blocking effects (Liu et al. 2011a; Bannister
et al. 2015). There are a few potential explanations
for these disparate findings, including a lower than
expected flecainide concentration within the cell in
Liu’s study, given rapid diffusion of neutral flecainide
through themembrane and repartitioning within the bath
solution, and potential mutation-induced lowered affinity
of flecainide for RyR2.
When we decoupled flecainide’s presumed RyR2
activity from its well-known Na+ channel blockade, we
were surprised to find that the model predicted that Na+
channel blockade – even at the high clinical doses –
was not sufficient to explain the antiarrhythmic effects
seen clinically with flecainide. As seen in Fig. 6 and 8
(single cells) and Fig. 9 (1D tissue), pure Na+ channel
Figure 14. Experimental test of predicted polytherapy
A and B, representative tracings from WT and R176Q/+ mice are
shown at baseline and after sympathetic challenge with no drug (A)
and following administration of flecainide, metoprolol and KN-93
(B). C, summary of data without (left) and following (right)
pre-treatment with flecainide, metoprolol and KN-93, which
suppressed VT in all R176Q/+ mice (∗P = 0.015).
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Table 7. ECG measurement comparing wild type and R176Q/+ mice before and after treatments
Without treatment With treatment
Baseline Epi + Caffeine Baseline Flec + Metop + KN-93 Epi + Caffeine
WT R176Q/+ P WT R176Q/+ P WT R176/+ P WT R176Q/+ P WT R176Q/+ P
Heart rate
(beats min−1)
574 462 0.18 588 466 0.09 442 467 0.73 385 375 0.93 424 328 0.25
PR (ms) 35 38 0.34 36 40 0.26 36 38 0.40 45 50 0.60 43 55 0.23
QRS (ms) 12 11 0.72 13 15 0.08 12 12 0.78 16 16 0.76 18 21 0.63
QTc (ms) 45 46 0.69 46 49 0.28 49 49 0.99 45 48 0.26 45 43 0.37
Adrenaline (2 mg kg−1) and caffeine (120 mg kg−1) were initially injected intraperitoneal (i.p.) without pre-treatment (Without
treatment). Mice were then given a pre-treatment dose of flecainide (12 mg kg−1, i.p.), metoprolol (10 mg kg−1, i.p.), and KN-93
(30 μmol kg−1, i.p.) followed 30 min later by an injection of the same i.p. dose of adrenaline and caffeine (With treatment). Flec,
flecainide (12 mg kg−1); Metop, metoprolol (10 mg kg−1); KN-93 (30 μmol kg−1).
blockade failed to inhibit spontaneous Ca2+ release, and
subsequent triggered activity, whereas the RyR2-specific
flecainide interaction was predicted to yield results similar
to flecainide acting on both targets.
Interestingly, our simulations with lidocaine (Moreno
et al. 2011) as an additional control of pure Na+
channel blockade resulted in good concordance with
experimental results (Katz et al. 2010; Galimberti &
Knollmann, 2011; Hwang et al. 2011), namely that as
a monotherapeutic approach, Na+ channel blockade
is insufficient to resolve CPVT arrhythmia triggers.
Consistent with experimental evidence in support of this
mechanism of action, flecainide’s interaction with the
Na+ channel did resolve arrhythmia triggers in higher
dimensions, but proarrhythmic DADs persisted.
Lastly, because the drugs used to treat CPVT act on
different targets, we hypothesized that their actions might
prove synergistic when used as a combination therapy.
We tested the full parameter space of clinically relevant
combination therapy with β-blockade, flecainide and
CaMKII inhibition (Fig. 12), and found that all three
drugs achieved better efficacy when used in combination
with either or both of the other drugs tested. The
potential to achieve therapeutic efficacy at lower drug
concentrations potentially limits the danger of off-target
and drug-related side-effects and are consistent with
clinical reports of improved therapy with combined
β-blockade and flecainide (Pott et al. 2011; Pflaumer &
Davis, 2012).
Importantly, our polypharmacy simulations go beyond
confirmation that a multidrug regimen is superior; for
the first time (to our knowledge), our simulations are a
proof-of-concept for prediction of a dosing strategy, and
simulate a virtual phase 1–2 clinical trial of dose escalations
with several thousand combinations of clinically relevant
dosages.
We then utilized an experimental protocol to validate
the virtual trial in R176Q/+ CPVT mice (Fig. 14). The
Table 8. Comparison of ECG measurements before and after
treatment with flecainide, metoprolol and KN-93
Flecainide,
Baseline Metoprolol, KN-93 P
Heart rate
(beats min−1)
461 378 0.14
PR (ms) 37 48 0.01
QRS (ms) 12 16 < 0.001
QTc (ms) 49 47 0.12
CPVT R176/+ mice developed bidirectional ventricular
tachycardia (VT) with catecholamine provocation. But,
as predicted by the computer model in both rabbit
(Fig. 12) and mouse (Fig. 13) virtual myocytes,
pre-treatment with flecainide,metoprolol andKN-93 pre-
vented catecholaminergically induced ventricular tachy-
cardia in all R176Q/+ mice.
Our study is not without limitations.Most importantly,
different CPVT mutations demonstrate differences in
ultrastructure (Liu et al. 2013), protein expression
(Song et al. 2007), RyR2 structural conformation and
functionality (Cerrone et al. 2005; Goddard et al. 2008),
and Ca2+ dynamics (Viatchenko-Karpinski et al. 2004;
Terentyev et al. 2006). As flecainide and β-blockade have
been used clinically, we know that the adverse effect
profiles are concentration dependent. Little is known
about the clinical consequences of CaMKII inhibition, and
our predictions will obviously require careful testing and
validation prior to clinical use.
Another important limitation of our study is that the
models that we have utilized do not explicitly represent
subcellular Ca2+ dynamics. For this reason, we are not
able to simulate subcellular Ca2+ waves and the effects
of the drugs on them. This will be an important sub-
ject of a future study. In addition, a full experimental
C© 2015 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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follow-up study to further test and hone the therapeutic
efficacy of alternate polytherapy approaches needs to be
conducted.
In conclusion, we utilized a computational modelling
approach, informed by, and validated with experimental
and clinical data, to make therapeutic predictions of drug
mechanism and efficacy in the setting of CPVT. Our study
sought to answer three fundamental questions of current
pharmacotherapy for CPVT. (i) Is flecainide interaction
with the Na+ channel sufficient for therapy? (ii) Can
we predict if other Na+ channel blockers will be equally
efficacious? (iii) Can a multi-targeted pharmacologic
approach synergize to yield greater success than with
individual therapeutics?
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